Chronic Cough Evaluation: A Systematic Diagnostic Approach
Initial Assessment and Red Flags
The ACCP 2024 updated guidelines recommend a systematic diagnostic protocol beginning with history, chest radiography, and ACE inhibitor discontinuation (cough resolves in 1-4 weeks after stopping in 50-80% of ACEi-associated cases). Red flags requiring expedited workup include hemoptysis, weight loss, fever, immunosuppression, progressive dyspnea, abnormal chest radiograph, and history of smoking with new or changed cough pattern. In nonsmokers with a normal chest radiograph who are not on ACE inhibitors, the three most common causes account for over 90% of cases: upper airway cough syndrome (UACS/postnasal drip, 34%), asthma/cough-variant asthma (25%), and gastroesophageal reflux (20%).
Upper Airway Cough Syndrome
UACS presents with nasal congestion, throat clearing, and sensation of postnasal drainage, though silent UACS without these symptoms occurs in 20% of cases. First-generation antihistamine-decongestant combinations (e.g., chlorpheniramine-pseudoephedrine or dexbrompheniramine-pseudoephedrine) are more effective than second-generation antihistamines due to anticholinergic properties (NNT 4-5 for cough resolution at 2 weeks). Intranasal corticosteroids (fluticasone 200 mcg daily or mometasone 200 mcg daily) are first-line for allergic rhinitis-driven cough, with a meta-analysis showing 36% reduction in cough scores. Empiric treatment trial of 2-4 weeks is both diagnostic and therapeutic.
Cough-Variant Asthma and Eosinophilic Bronchitis
Cough-variant asthma presents with isolated cough (no wheeze or dyspnea) and is confirmed by positive methacholine challenge (PC20 below 8 mg/mL) or reversible airflow obstruction on spirometry (FEV1 improvement of 12% and 200 mL post-bronchodilator). Inhaled corticosteroids (budesonide 200-400 mcg twice daily or fluticasone 125-250 mcg twice daily) are the treatment of choice, with cough resolution expected within 6-8 weeks. Non-asthmatic eosinophilic bronchitis (NAEB) accounts for 10-15% of chronic cough cases and is distinguished from asthma by normal methacholine challenge but elevated induced sputum eosinophils (above 3%). NAEB responds to inhaled corticosteroids with comparable efficacy.
Sponsored
Reflux-Associated Cough
GERD-related cough may occur without typical heartburn or regurgitation in up to 75% of cases (silent reflux). Empiric PPI therapy (omeprazole 40 mg daily or equivalent) for 8-12 weeks is the standard diagnostic-therapeutic approach. However, the COUGH-1 and COUGH-2 trials showed only modest benefit of PPIs over placebo for chronic cough, with NNT of 10-12. Ambulatory pH monitoring (24-hour catheter-based or wireless Bravo capsule) with symptom association probability (SAP above 95%) or symptom index (SI above 50%) provides objective evidence of reflux-cough association. Impedance-pH testing detects both acid and non-acid reflux events, increasing diagnostic sensitivity to 90%.
Refractory and Unexplained Chronic Cough
Approximately 5-15% of chronic cough cases remain unexplained despite comprehensive evaluation. Cough hypersensitivity syndrome, characterized by enhanced cough reflex sensitivity to environmental and chemical triggers, is increasingly recognized as the unifying mechanism. Gabapentin (300-1800 mg daily) reduced cough-specific quality of life by 33% compared to placebo in the randomized trial by Ryan et al. (NNT 3.6). Speech pathology-based cough suppression therapy achieves 50-60% improvement in cough frequency. The P2X3 receptor antagonist gefapixant (45 mg twice daily) was FDA-approved in 2025 for refractory chronic cough, reducing cough frequency by 18.5% versus placebo (COUGH-1 trial), though taste disturbance (dysgeusia) occurs in 58% of patients at therapeutic doses.
Sponsored
Want to try Ailva?
Ailva is a clinical intelligence platform that delivers evidence-based answers with verified citations and cross-system reasoning. Free for all NPI holders.